Axovant Gene Therapies Ltd., a company developing innovative gene therapies, has announced they are entering the next stage of a phase II gene therapy trial for Parkinson's.
The STEADY-PD clinical trial has failed to show that isradipine is an effective treatment to slow or stop progression in early Parkinson's.
The government initiative to fast-track access to new treatments and services is being expanded, potentially shaving years off the time it takes for people with Parkinson's to benefit from innovations in research.
Results from a trial of spinal cord stimulation carried out in Ontario, Canada highlights its potential for improving walking in Parkinson's.
Figures released on World Parkinson's Day reveal astonishing levels of harassment and discrimination faced by people with Parkinson's.
Figures reveal for the first time the shocking lack of public awareness around Parkinson's and its symptoms despite it being the second most prevalent neurodegenerative condition after Alzheimer's.